---
title: "Zhengda Tianqing's oral biased GLP-1 receptor agonist TQF3250 has submitted for clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258454207.md"
description: "On September 23rd, Chengda Tianqing Pharmaceutical Group's self-developed Class 1 innovative drug TQF3250's clinical trial application was accepted by the National Medical Products Administration, intended for the treatment of type 2 diabetes. In addition, the clinical trial protocol for TQF3250 also includes the exploration of weight loss indications"
datetime: "2025-09-23T04:43:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258454207.md)
  - [en](https://longbridge.com/en/news/258454207.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258454207.md)
---

# Zhengda Tianqing's oral biased GLP-1 receptor agonist TQF3250 has submitted for clinical trials

On September 23, Chengda Tianqing Pharmaceutical Group's self-developed Class 1 innovative drug TQF3250's clinical trial application was accepted by the National Medical Products Administration, intended for the treatment of type 2 diabetes. In addition, the clinical trial protocol for TQF3250 also includes the exploration of weight loss indications

## Related News & Research

- [BUZZ-Street View: Pfizer's monthly obesity shot awaits key late-stage study results](https://longbridge.com/en/news/289042459.md)
- [Marvell shares jump after chipmaker wins spot in S&P 500](https://longbridge.com/en/news/289050820.md)
- [Lilly shares jump as analysts see retatrutide data extending obesity market edge](https://longbridge.com/en/news/289044514.md)
- [Elon Musk Reacts To $30 Trillion SpaceX Valuation Call: 'Ron Is Smart'](https://longbridge.com/en/news/289017271.md)
- [Why the $1 Trillion Wipe Out Did Not Matter](https://longbridge.com/en/news/289023077.md)